<DOC>
	<DOC>NCT00479583</DOC>
	<brief_summary>The purpose of this research study is to determine the highest dose of BMS-690514 that can be safely given in combination with the chemotherapeutic regimens (FOLFIRI and FOLFOX) to patients with advanced cancer</brief_summary>
	<brief_title>Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX</brief_title>
	<detailed_description />
	<criteria>Patients eligible for FOLFIRI or FOLFOX therapy ECOG performance status score 01 At least 4 weeks since the last chemotherapy, immunotherapy or radiotherapy with: At least 4 weeks since anticancer hormonal therapy OR targeted therapy (for instance tamoxifen or Tarceva) No maximum age for Study Arm A (FOLFOX) 1865 years of age for Study Arm B (FOLFIRI) Treatment with other TKIs within the past 4 weeks Active inflammatory bowel disease Major gastrointestinal surgery which may affect absorption of the drug, any surgery within the last 4 weeks History of thromboembolism Severe unmanageable diarrhea Uncontrolled or significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Cancer (solid tumors)</keyword>
</DOC>